Multiple Myeloma – Sanofi LPS18183

Patient and caregiver smiling

The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.

Inclusion Criteria:

  • Must be 18 years or older
  • Participants must have a documented diagnosis of MM
  • Participants with relapsed and/or refractory MM with at least 1 prior line of therapy and no more than 3 prior lines of therapy
  • Capable of giving signed informed consent

Call us at 248-282-3640 or complete the form and our team will reach out soon to help determine your eligibility.

Trial Interest Form

Locations

Michigan Healthcare Professionals TriAtria

32255 Northwestern Hwy
Suites 130 & 160
Farmington Hills, Michigan

Michigan Hematology & Oncology Consultants

13530 Michigan Ave
Suite 280
Dearborn, Michigan